WO2008086538A1 - Branched chain amino acid chelate - Google Patents
Branched chain amino acid chelate Download PDFInfo
- Publication number
- WO2008086538A1 WO2008086538A1 PCT/US2008/050974 US2008050974W WO2008086538A1 WO 2008086538 A1 WO2008086538 A1 WO 2008086538A1 US 2008050974 W US2008050974 W US 2008050974W WO 2008086538 A1 WO2008086538 A1 WO 2008086538A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- mineral
- branched
- percent
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to nutritional compositions. More specifically, the invention relates to dietary supplements for increasing branched-chain amino acid delivery and for methods of providing increased levels of branch-chain amino acids utilizing dietary supplements, Background of the Invention
- Mineral absorption generally occurs in the small intestine via a combination of active, or transcellular, absorption and passive, or paracellular, absorption.
- nutritional supplementation of foods with minerals has become common and a primary method for providing minerals in foods and in supplements is to provide them as chelates formed with amino acids or peptides to improve absorption of the mineral.
- Minerals provided in the chelated form are more available for absorption. Studies in animals, for example, have demonstrated that chelated minerals provided in the diet result in higher mineral absorption and utilization.
- AAFCO American Association of Feed Control Officials
- Patent application publication number 2002/0058088 (Henry et al.) describes chelates of alpha- amino acids for producing color stable iron-fortified compositions, where the ligand to metal ratio is at least 2:1.
- U.S. Patent application publication number 2005/0239763 (Motyka et al.) describes a metal amino acid chelate composition having an amino acid to metal molar ratio of from about 1 :1 to 4:1 , as does U.S. Patent application publication number 2005/0239750 (Motyka et al.).
- U.S. Patent application publication number 2003/0206969 discloses an iron/amino acid chelate having a metal: ligand ratio of 1 :1-3.
- Amino acids are generally considered to be efficiently absorbed in the normal human or animal intestine, but not all ingested amino acids are well-absorbed.
- BSA bovine serum albumin
- the amino acids alanine, phenylalanine, arginine, leucine, methionine, and tyrosine were absorbed at a rate of 50% or more (e.g., 86% for methionine).
- Other amino acids, such as cystine (3%) were absorbed at much lower rates.
- BCAAs branched- chain amino acids
- Amino acid supplementation is generally accomplished by ingesting higher-protein foods, isolated proteins and/or amino acids, or hydrolyzed proteins.
- Aqueous formulations of the branched-chain amino acids which would provide a formulation that could be more easily consumed by individuals who might particularly benefit from BCAA supplementation, are difficult to prepare because BCAAs have non-polar side groups and are hydrophobic.
- the present invention relates to a mineral branched-chain amino acid chelate.
- the invention relates to a leucine chelate such as calcium leucinate.
- the mineral can comprise a mono- or divalent cation such as calcium, magnesium, potassium or zinc and the branched-chain amino acid can comprise isoleucine or valine.
- One aspect of the invention relates to methods of incorporating branched-chain amino acids into food or nutritional supplement products.
- a method for incorporating branched-chain amino acids into liquid or aqueous food or supplements is provided, the method comprising providing one or more branched-chain amino acids in the form of a BCAA/mineral chelate.
- the invention also relates to methods of use of BCAA chelates to provide increased levels of BCAAs to a human or animal subject via food and/or nutritional supplementation.
- nutritional supplementation may comprise a nutritional supplement product such as a powder, capsule, tablet, or nutritional drink, for example.
- nutritional supplementation may comprise supplementation of a food or feed product.
- composition of the invention comprises a combination of one or more BCAA/mineral chelates and a whey protein product such as whey protein concentrate or whey protein isolate.
- the invention is a composition comprising a mineral/branched- chain amino acid chelate formed by chelating a mineral such as calcium or magnesium using leucine or other branched chain amino acid as the chelating amino acid.
- the composition is formed by reacting a mineral source, such as, but not limited to, calcium or magnesium carbonate, with free leucine, or other branched chain amino acid (BCAA), to form, in one embodiment, calcium leucinate.
- a mineral source such as, but not limited to, calcium or magnesium carbonate
- BCAA free leucine, or other branched chain amino acid
- the mineral can comprise, for example, calcium, magnesium, potassium or zinc and the branched-chain amino acid can comprise leucine, isoleucine or valine.
- the mineral moiety of a composition of the invention can be provided by, for example, calcium chloride, calcium carbonate, calcium citrate, calcium lactate, calcium gluconate, calcium phosphate, milk calcium, coral calcium, egg shell calcium, calcium hydroxide, calcium sulfate, magnesium chloride, magnesium carbonate, magnesium citrate, magnesium oxide, magnesium phosphate, magnesium hydroxide, magnesium lactate, magnesium sulfate, zinc sulfate, zinc citrate, zinc gluconate, zinc picolinate, zinc chloride, zinc oxide and/or other calcium, magnesium, zinc, or potassium salts.
- Other appropriate sources of mono- or divalent cations such as calcium, magnesium, zinc, or potassium, for example, are known to those of skill in the art and may be used in the present composition.
- BCAA/mineral chelates of the invention provide an amino acid that is more easily incorporated into the final product.
- compositions of the present invention may comprise from about 75 to about 80 percent leucine and from about 10 to about 12 percent calcium.
- a calcium leucinate composition comprises a calcium to leucine molar ratio of 1 to 2.
- compositions can comprise, by weight, from about 40% to about 90% amino acid and from about 5 to about 60 percent mineral.
- compositions may comprise from about 10 to about 40 percent mineral in combination with from about 60 to about 90% amino acid.
- Compositions may also comprise from about 75 to about 80 percent amino acid and from about 20 to about 25% percent mineral.
- compositions of the invention may be incorporated into formulations including, but not limited to, a full range of beverages, bars, foods, animal feeds, powders, drinks, or provided as supplement tablets, caplets, capsules, or other formulations for human or animal use.
- Compositions described by the invention may be used to provide increased availability of branched-chain amino acids, which are known to play important roles in a variety of metabolic processes.
- Branched- chain amino acids L-leucine (2-amino-4-methylvaleric acid; alpha- aminoisocaproic acid; (S)-2-amino-4-methylpentanoic acid, chemical formula C6H13NO2), L-valine (2-aminoisovaleric acid; 2-amino-3-methylbutyric acid; alpha-aminoisovaleric acid; (S)-2-amino-3-methylbutanoic acid; chemical formula C5H11 NO2); and L-isoleucine (2-amino-3-methylvaleric acid; alpha- amino-beta-methylvaleric acid; (2S,3S)-2-amino-3-methyl pentanoic acid; chemical formula C6H13NO2) play important roles, for example, in modulation of protein turnover and recovery from mental fatigue.
- leucine has been shown to be a specific modulator of protein turnover (Bevington, A. et al. Eur. J. Clin. Invest. (2001 ) 31 (6): 497-503) and branched-chain amino acids have been shown to decrease muscle proteolysis via inhibition of lysosomal proteolysis (Busquets, S. et al. J. Cell Physiol. (2000) 184(3): 380-
- compositions of the present invention provides a method for increasing the availability of BCAAs in food and nutritional supplements and related products and providing a therapeutic benefit for building and/or maintaining muscle tissue where loss of muscle tissue is associated with conditions that include, but are not limited to, stroke, spinal cord injury, osteoarthritis, rheumatoid arthritis, prolonged corticosteroid therapy, diabetic neuropathy, burns, amyotrophic lateral sclerosis (ALS), Buillain-Barre Syndrome, Muscular Dystrophy, sarcopenia associated with aging, and muscle tissue loss associated with weightlessness in astronauts.
- ALS amyotrophic lateral sclerosis
- Administration may be accomplished by oral or enteral means, and compositions may include tablets, caplets, gelatin capsules, powders, nutritional foods, nutritional drinks, enteral feeding formulations, and the like, comprising at least one BCAA/mineral chelate of the invention.
- the invention provides nutritional therapies for individuals having the aforementioned conditions, as well as for athletes desiring to build and/or maintain muscle mass and improve muscle strength. The invention may also provide a nutritional means to decrease mental fatigue.
- compositions of the invention may be provided as tablets, caplets, gelatin capsules, chewable tablets, a supplemented drink, nutrition bar, or other formulation to provide at least one BCAA/mineral chelate to an individual to decrease mental fatigue following, for example, strenuous exercise or physically- demanding work.
- BCAA/mineral chelates of the invention may also be administered in a method of the invention to increase BCAA absorption and decrease central fatigue after exercise.
- Table 1 lists ingredients comprising an example of a composition comprising a powdered formulation to provide a nutritional drink as provided by the invention.
- WPC whey protein concentrate
- WPI Whey protein isolate
- Chelated leucine may be present in such a composition from about 0.1 gram to about 2 grams, and crystalline fructose may be present from about 10 grams to about 20 grams.
- compositions of the invention may comprise at least about about 0.1 grams of leucine, isoleucine, valine, or combinations thereof, and preferably will be formulated to provide at least about 3 grams daily of leucine, isoleucine, valine, or combinations thereof.
- Compositions may be provided for occasional or for regular use, with regular use being preferred. Regular use may include daily, twice-daily, every other day, or other regimens, for example. For improved effect, administration of at least 3 grams of leucine per day, for example, may be preferred.
- compositions of the invention providing, for example, BCAA/mineral chelates for use in aqueous formulations, powders dispersed in aqueous formulations, or similar compositions, increase availability of BCAAs to human or animal subjects to whom they are provided or administered.
- a method for providing branched-chain amino acids in a liquid beverage comprising forming a branched-chain amino acid chelate and adding the chelate to the beverage.
- the inventors attempted to incorporate free leucine and microencapsulated free leucine into beverages and found both products difficult to use and difficult to disperse.
- the microencapsulated leucine produced a turbid, cloudy solution, indicative of non-dissolving particulates.
- Free leucine showed a separation phenomenon in aqueous solution.
- a BCAA/mineral chelate of the invention was utilized, however, the chelated leucine product was much more easily dispersed and did not separate or increase turbidity of aqueous systems.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88489007P | 2007-01-14 | 2007-01-14 | |
| US60/884,890 | 2007-01-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008086538A1 true WO2008086538A1 (en) | 2008-07-17 |
Family
ID=39609084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2008/050974 Ceased WO2008086538A1 (en) | 2007-01-14 | 2008-01-14 | Branched chain amino acid chelate |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008086538A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2865382B1 (en) | 2009-12-24 | 2018-01-17 | N.V. Nutricia | Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis |
| EP2768322B1 (en) | 2011-10-21 | 2018-05-30 | Nestec S.A. | Whey protein micelles against muscle atrophy and sarcopenia |
| RU2686086C1 (en) * | 2018-05-17 | 2019-04-24 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Method for correction of pre-sarcopenia or sarcopenia correction in a patient with adequate consumption of essential nutrients receiving programmed hemodialysis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6299914B1 (en) * | 1999-11-01 | 2001-10-09 | Albion International, Inc. | Compositions and methods for calcium fortification of dairy products and oleaginous foods |
-
2008
- 2008-01-14 WO PCT/US2008/050974 patent/WO2008086538A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6299914B1 (en) * | 1999-11-01 | 2001-10-09 | Albion International, Inc. | Compositions and methods for calcium fortification of dairy products and oleaginous foods |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2865382B1 (en) | 2009-12-24 | 2018-01-17 | N.V. Nutricia | Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis |
| EP2768322B1 (en) | 2011-10-21 | 2018-05-30 | Nestec S.A. | Whey protein micelles against muscle atrophy and sarcopenia |
| RU2686086C1 (en) * | 2018-05-17 | 2019-04-24 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Method for correction of pre-sarcopenia or sarcopenia correction in a patient with adequate consumption of essential nutrients receiving programmed hemodialysis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU774654B2 (en) | Bioavailable chelates of creatine and essential metals | |
| EP1536781B1 (en) | Nutritional or pharmaceutical compositions for increasing the creatine response of organisms | |
| Flodin | The metabolic roles, pharmacology, and toxicology of lysine. | |
| CA2645178C (en) | Mixed amino acid mineral chelates and compositions having improved solubility | |
| CN108024981B (en) | A kind of carboxylic acid composition for treating patients with nephropathy | |
| US6667063B2 (en) | Nutritional or therapeutic supplement and method | |
| JP2024122087A (en) | Free amino acid absorption enhancer and method for enhancing absorption of free amino acids | |
| CN101528066A (en) | Long-term feed - cancer patient | |
| US6294207B1 (en) | Calcium fortification of oleaginous foods | |
| EP3184107A1 (en) | Method and preparation for treating metabolic stress | |
| US20090042770A1 (en) | Branched Chain Amino Acid Chelate | |
| CN101166429A (en) | Alimentation composition | |
| JP2002065212A (en) | Food composition for strengthening muscle, and muscle- strengthening agent | |
| WO2007069072A2 (en) | Salts of mineral nutrients stabilized with amino acids and/or ammonium salts, products and food supplements that contain them and methods for obtaining same | |
| WO2008086538A1 (en) | Branched chain amino acid chelate | |
| ES2295223T3 (en) | ALFA-CETOGLUTARATES OF ACTIVE PRINCIPLES AND COMPOSITIONS THAT CONTAIN THEM. | |
| US20040048925A1 (en) | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives | |
| RU2255604C2 (en) | Biologically active food additive preventing calcium deficiency and optimizing calcium metabolism, and food product containing thereof | |
| US20040220266A1 (en) | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives | |
| CN101402583B (en) | Levorotation carnitine acid calcium phosphate, preparation method and use thereof | |
| US11970435B2 (en) | Taste-modified creatine salts, compounds, compositions and uses thereof | |
| JPH0515339A (en) | Protein-like composition, nourishing medicine for serious stress and nourishing medicine for hepatic disease | |
| JPS595111A (en) | Nutritional preparation for infants with phenylketonuria | |
| JP2010095474A (en) | Calcium absorption-promoting composition and calcium absorption-promoting food and drink | |
| US20190175533A1 (en) | Nutritional supplement for improved calcium absorption |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08727633 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2009545722 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08727633 Country of ref document: EP Kind code of ref document: A1 |